SCHEMBL1348136

SCHEMBL1348136

O=C(O)CCCC=CC[C@H]1[C@@H](O)CC(=O)[C@@H]1C=CC(O)CCCc1cc2ccccc2s1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 3/20 0.63
ALDH1A1 P00352 2/20 0.63
SLCO2A1 Q92959 2/20 0.63
PTGER4 P35408 7/20 0.53
PTGER3 P43115 5/20 0.53
PTGER1 P34995 3/20 0.53
PTGFR P43088 7/20 0.50
TBXA2R P21731 3/20 0.46
PTGER2 P43116 2/20 0.46
PTGIR P43119 2/20 0.46
NR1I2 O75469 1/20 0.46
ESR1 P03372 1/20 0.46
PGR P06401 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
OPRK1 P41145 1/20 0.46
PDE4D Q08499 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1348138 1.00 PTGDR2 (0.63) PTGDR2ALDH1A1SLCO2A1PTGER4PTGER3
SCHEMBL1348133 1.00 PTGDR2 (0.63) PTGDR2ALDH1A1SLCO2A1PTGER4PTGER3
SCHEMBL1348165 0.87 PTGER4 (0.63) PTGER4PTGER3PTGER1PTGFRTBXA2R
SCHEMBL1348173 0.87 PTGER4 (0.63) PTGER4PTGER3PTGER1PTGFRTBXA2R
SCHEMBL1348171 0.87 PTGER4 (0.63) PTGER4PTGER3PTGER1PTGFRTBXA2R
SCHEMBL1347031 0.86 PTGDR2 (0.56) PTGDR2ALDH1A1SLCO2A1PTGER4PTGER3
SCHEMBL1347024 0.86 PTGDR2 (0.56) PTGDR2ALDH1A1SLCO2A1PTGER4PTGER3
SCHEMBL1347027 0.86 PTGDR2 (0.56) PTGDR2ALDH1A1SLCO2A1PTGER4PTGER3
SCHEMBL1347390 0.84 PTGER4 (0.54) PTGDR2ALDH1A1SLCO2A1PTGER4PTGER3
SCHEMBL1347388 0.84 PTGER4 (0.54) PTGDR2ALDH1A1SLCO2A1PTGER4PTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063240-B2 Prostaglandin E1 and E2 analogs for the treatment of various medical conditions CAYMAN CHEMICAL COMPANY, INCORPORATED (US) 2011-11-22 US disclosed
US-20090221654-A1 PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS CAYMAN CHEMICAL COMPANY (US) 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221654-A1 PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS PTGER1, PTGER4, PTGER2 PTGDR2 11/4885ALDH1A1 594/4885SLCO2A1 4636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.